1. Investigation of Carbapenemase-Producing Pseudomonas aeruginosa at Secondary Care Hospital in Bolu, Turkey.
- Author
-
Kalaycı Çekin Z, Tanrıverdi ES, and Otlu B
- Subjects
- Turkey epidemiology, Humans, Carbapenems pharmacology, Secondary Care Centers, Drug Resistance, Multiple, Bacterial genetics, Cross Infection microbiology, Cross Infection drug therapy, Cross Infection epidemiology, Male, Female, Middle Aged, Adult, beta-Lactamases genetics, Pseudomonas aeruginosa genetics, Pseudomonas aeruginosa drug effects, Pseudomonas aeruginosa isolation & purification, Bacterial Proteins genetics, Anti-Bacterial Agents pharmacology, Pseudomonas Infections microbiology, Pseudomonas Infections drug therapy, Pseudomonas Infections epidemiology, Microbial Sensitivity Tests
- Abstract
The global increase in carbapenem resistance poses a significant public health threat due to the potential emergence of multidrug-resistant pathogens and limited treatment options. To learn more about this issue and offer potential solutions, we conducted a study of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections in a secondary care hospital setting. The study utilized the carbapenem inactivation method (CIM), a leading phenotypic analysis, to determine carbapenemase activity in 63 CRPA isolates. Additionally, polymerase chain reaction (PCR) analysis was conducted to test for the presence of carbapenemase genes associated with the production or expression of various carbapenemase enzymes, including bla
KPC , blaNDM , blaVIM , blaOXA-48 , blaIMP , and blaGES . Arbitrary primed PCR (AP-PCR) was performed to assess the clonal relationship between different isolates. The isolates were also classified as either health care-associated infections or community-acquired infections, and their clonal relationship and gene positivity were evaluated. A total of 63 CRPA samples underwent evaluation, with 14 isolates determined to be carbapenemase producers via CIM tests. PCR assays revealed that 14 isolates carried carbapenemase genes, with 9 carrying blaNDM , 2 carrying blaGES , 2 carrying blaVIM , and 1 carrying blaIMP . CRPA exhibited a 22% prevalence of carbapenemase genes, of which 64% were attributed to the NDM gene responsible for multidrug resistance. AP-PCR revealed high clonal diversity among the isolates. Molecular epidemiological evaluation also showed no dominant outbreak strain among PA isolates. This study presents significant data on the prevalence and distribution of carbapenemase-producing CRPA strains isolated from secondary health care facilities. Typically, the literature focuses on resistance rates in tertiary care public hospitals. These findings may aid in understanding resistance and its mechanisms, as well as in developing effective treatment strategies and infection control measures.- Published
- 2024
- Full Text
- View/download PDF